(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Fate of Mechanical technology: 5 Headways Forming Tomorrow - 2A few Exemplary Chinese Dishes, Which Are Famous Around the world
- 3Knesset FADC extends emergency draft for 280,000 IDF reservists until January 1
- 4Here's what can happen if you drive under the influence of pot
- 5The 10 Most Compelling Forerunners in Innovation
- The most effective method to Boost Eco-friendliness in Your Volvo XC40
- 5 High Limit Outer Hard Drives For Information Stockpiling
- Vice President Dick Cheney’s life followed the arc of the biggest breakthroughs in cardiovascular medicine
- Pick Your Favored kind of sandwich
- Los Angeles County sees significant uptick in norovirus cases, officials say
- Euclid space telescope sees gorgeous cosmic cloud | Space photo of the day for Nov. 18, 2025
- The 15 Most Rousing TED Chats on Self-awareness
- Sound and Delightful: 12 Nutritious Smoothie Recipes
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
